Member Info for draft

Im not going to bother posting here anymore, given that mickey mouse character advantage.

Immedia sent some Ikea tweet out.

Quite obious wwho the mickey mouse blogger is - so bleeding obvious.

LOL im not that fricking stupid, Ive been trapped in this share for almost 2 years now - im not adding anymore.

im like 95% down from when i originally bought in here, these guys are more bent than a bent nail

these guys will get a deal. someone will want these gas resources

IME immedia provide all the music and app branding for JD sports, might explain the JD results, just all around better experience. i have shares in ime.

LOL there is nothing cloak and dagger here at all. you sure your not that mickey mouse character off that blog?

B Rad Tech will be used to assess brain tumour treatment response in multi-center trial

Â

Imaging Biometrics®, LLC ("IB"), a wholly-owned subsidiary of Flying Brands Limited (LON:FBDU), and the American College of Radiology Imaging Network ("ACRIN") have united efforts in a multi-center Phase II trial sponsored by the Eastern Cooperative Oncology Group (ECOG)-ACRIN Cancer Research Group. The study will use IB Rad Tech™ to post-process datasets acquired from over 20 US sites to determine how well dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with recurrent glioblastoma, and to ultimately correlate changes in rCBV to overall survival (OS) and progression free survival (PFS).

Â

Patients enrolled in the study will undergo a DSC-MRI exam right before beginning treatment with bevacizumab (Genentech, San Francisco). After the baseline exam, follow-up DSC-MRI exams will be scheduled prior to the second dose administration of bevacizumab, typically 2-3 weeks after the initial dose. In total, 165 patients are estimated to participate in the study.

Â

IB Rad Tech, a customizable software interface, acts as a "workflow wizard" to guide users through a series of automated processing steps. The specific workflow used in this study will leverage IB's FDA cleared software modules IB Neuro and IB Delta Suite to easily determine the tumor region of interest (ROI) and compute DSC-MRI-based normalized and standardized rCBV maps. Exclusive to IB, standardization is a machine-learned calibration approach that translates relative MR values to a fixed and consistent scale regardless of scanner vendor, field strength, or patient. The ability to automatically generate quantitative rCBV values consistently, independent of scanner or timepoint, makes it ideal for longitudinal assessment of treatment response.

Â

ACRIN Principal Investigator Jerrold L. Boxerman, MD, PhD, Associate Professor of Diagnostic Imaging at The Warren Alpert Medical School of Brown University and Fellow of the American College of Radiology, said "This study will help determine if rCBV can serve as an early response imaging biomarker to an anti-angiogenic agent (bevacizumab) in patients with recurrent brain cancer. If successful, rCBV will lead the way for the incorporation of more advanced imaging biomarkers into clinical trials, which should help to improve the development efforts for new cancer treatments. IB Rad Tech's ability to quantify how patients are responding to treatment will provide for a more robust study and greatly simplifies the post-processing of the numerous datasets that we will acquire."

Michael Schmainda, CEO of IB said "We are delighted IB Software was chosen for this important multi-center trial. Our quantitative analysis resolves many inconsistencies that have inhibited routine and robust brain tumour assessment, and has

ixicos a big avoid right now - its already risen. we also have a phase 2 trial

Iguess most peopel sold at a loss after the last ridiculosu placing here, I used to be in this, bad placing price and now 60%. hate the way it does down on aim sometimes, anyway FBDU also do neuro products and worth checking out as its running away right now

https://www.ft.com/content/0bf8e56c-b587-11e8-bbc3-ccd7de085ffe

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/0bf8e56c-b587-11e8-bbc3-ccd7de085ffe

Shops still work.

In an era where most retailers are looking to reduce their physical footprint, JD Sports said in its interim results statement that it expects physical stores “to retain most of their current level of importance.”

“We do not anticipate a material movement in the size of our store base in the UK and Ireland although we continue to work with landlords on ensuring that our portfolio of leases has the maximum flexibility and the lowest committed cost possible”.

The group, which has 390 sports fashion stores in the UK and Ireland, added that it expects to report full-year profit in line with market forecasts after its UK operations increased sales in the first half of the year.

The group, which prides itself on its close relationships with suppliers such as Nike and Adidas, reported operating profit of £123.9m for the six months to August 4, against £103m in the equivalent period last year. Finish Line, the US operation acquired in June, contributed £4.8m for the seven weeks of the period.

Peter Cowgill, JD’s executive chairman, said:

“Against a backdrop of widely reported retail challenges in the UK, it is extremely reassuring that the profitability in the UK and Ireland Sports Fascias has been further enhanced. This reflects the value of the investments that we have made over a number of years in developing a dynamic multichannel proposition.”

The company’s UK operations are largely mature, with much of its growth now coming from expansion in Europe and Asia. In the US, it said it will start a trial of JD Sports fascia this year.

The Outdoor division, which includes brands such as GoOutdoors, Blacks Leisure and Milletts, had a more difficult half owing to the hot summer weather, which curtailed sales of weatherproof clothing.

Flying Brands, the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share

im not selling when this comes back. Sorrell could make this worth billions and he owns the majority of the shares so i doubt he will be selling.

Will
a) either paying more later
b) probably cursing us for walking off with the major reward

It is quite obvious David Smith aint messing around. We are well placed to GLOBALLY send out both existing software. An of course can not rule out further acquisitions in maybe the lung or cardiac space.

CHICAGO, May 3, 2017 /PRNewswire/ -- Chicago based Rheoxtech LLC has appointed David W.J. Smith as its first President. David has 30 years' experience in founding, developing and providing successful exits for medical device businesses and their investors. He originally started his career in the UK, before moving to the US and immersing himself in medical device startup companies in the San Francisco Bay Area. His most recent notable success was as the founding CEO of Tenaxis Medical Inc, a surgical sealant business. He coordinated the development, regulatory approvals and product commercialization for the company. He assisted in raising $22M for the company over 4 different funding series. Tenaxis Medical was acquired by The Medicines Company in 2014 for a payment of up to $178M. Beyond this, David has deep and broad experience in the fields of interventional cardiology, cardiac and vascular surgery, general surgery and ophthalmology.

Rheoxtech was founded by cardiac surgeon Neil J. Thomas MD and serial entrepreneur Gintaras Vaisnys. It is building on the pioneering work of Dr Thomas, a longtime proponent of controlling cardiac oxygen re-exposure as part of the protection of the heart during surgery, particularly for patients that are hemodynamically unstable and those in cardiogenic shock.

Mr. Vaisnys commented, "We are delighted to attract someone of David's caliber to this critical role. He has exactly the right blend of project management, fund raising and business development experience we were seeking to drive outstanding shareholder returns."

Rheoxtech LLC is a closely held private company, committed to the development of devices for protected reperfusion in percutaneous coronary intervention (PCI) and cardiac surgery.

yes Nagy and this FBDU rns confirms that we are expecting sales in Korea.

i like this share - theres no drilling risk, no spud, no topsoil movement, the cost base here is generally very low. Imaging Biometrics acquistion was a masterstroke.

IB also completed the code modifications required to port its software to a PC-based DICOM viewer. The viewer is analogous to the Apple (Mac) based platform, OsiriX, which was the initial host platform for IB software "plug-ins". This is a significant opportunity as the vast majority of health care systems and clinics are predominately PC-based. Thus, it is anticipated that sites who are interested in accessing IB's advanced imaging solutions will find an easier path for adoption with a PC-based offering.

The IB Clinic suite of products is currently being evaluated by a number of leading institutions for incorporation into their radiology practices and we have seen a marked increase in the number of demonstrations requested for our suite of software products from opinion leading institutions. We would expect some of these inquiries to be converted into sales revenue during H2 2018 and H1 2019.

The DICOM thing is a huge game changer for IB.

I am surprised more people are not commenting on the Revenue growth of IB. half year faster than the whole of last year

guys. just leave it now. if he posts again on feedback then fine your welcome here to rinse. ill keep an eye on feedback also.

Okay, I hope no further comments, comments like that dont help anyone. I will keep eye on FDBK bb also